Skip to main content
Premium Trial:

Request an Annual Quote

Infinimmune, Grid Therapeutics Strike Antibody-Based Cancer Drug Discovery Partnership

NEW YORK — Antibody drug discovery and development firm Infinimmune said on Tuesday that it has partnered with Grid Therapeutics to identify new drug candidates for non-small cell lung cancer.

Under the terms of the deal, the companies will use Infinimmune's Anthrobody drug-discovery platform and its Complete Human immunosequencing technology to study the antibody repertoire of non-small cell lung cancer patients and control patients selected on the basis of their clinical status and response to standard-of-care chemotherapies and immunotherapies.

The companies aim to use this data to understand differences and similarities between the antibody responses of individuals with lung cancer progression, according to San Francisco-based Infinimmune.

"We aim to take full advantage of Infinimmune's truly human antibody data, to efficiently identify better and safer therapeutics," Grid CEO Edward Patz said in a statement.

Grid, based in Durham, North Carolina, currently has two antibody-based drugs in clinical development, both for non-small cell lung cancer.